The advertising and promotion of medicines is one of the most carefully regulated commercial activities in Iraq’s pharmaceutical sector. The regulatory philosophy reflects a global consensus: medicines are not ordinary consumer goods, and their promotion must be balanced against patient safety, prescriber autonomy, and the integrity of clinical decision-making. For commercial teams accustomed to the freer environment of consumer marketing, the constraints can feel restrictive; for compliance teams, they are an essential framework that prevents the harms that come from unrestrained promotion of products with significant clinical risk profiles.
The legal framework comprises Public Health Law No. 89 of 1981, ministerial instructions on advertising of medicines, the Pharmacy Profession Law, and professional codes of conduct issued by relevant syndicates. General advertising and consumer protection law also applies, and a single promotional activity may be reviewed against multiple legal standards simultaneously.
Core Principles
Promotional activities for medicines must be truthful, accurate, balanced, and supported by approved product information. Promotional claims cannot exceed the indications, dosage, contraindications, and warnings recorded in the marketing authorization. Comparative claims must be supported by adequate evidence. Promotion of unregistered indications, off-label promotion is prohibited and is one of the more common areas of enforcement risk for pharmaceutical companies that have not adapted their global messaging to the Iraqi authorization context.
Direct-to-Consumer Advertising
Direct-to-consumer advertising of prescription medicines is generally not permitted in Iraq. This restriction covers television, radio, newspapers, magazines, billboards, and digital media. The rationale is that prescription decisions should be made by qualified healthcare professionals based on clinical assessment, not driven by consumer demand stimulated by advertising. Over-the-counter medicines may be advertised to the public, subject to approval of the advertising content by the Ministry of Health and compliance with general advertising standards, and the rules on what kinds of claims may be made even for OTC products are themselves quite specific.
Promotion to Healthcare Professionals
Promotion to healthcare professionals is permitted but regulated. Promotional materials directed at HCPs must be consistent with approved product information, submitted to the Ministry of Health for review or notification, and balanced in presentation of benefits and risks. Claims must be supported by reliable references. Promotional materials include printed brochures, journal advertisements, samples, and electronic content, and the review framework increasingly extends to digital channels. Medical sales representatives play a central role in HCP promotion in Iraq and must be appropriately trained on the products they promote, on the regulatory environment, and on the boundaries of acceptable promotional behavior.
Samples
Provision of samples to HCPs is permitted but limited. Samples should be provided upon request and in quantities consistent with professional needs, not for sale or commercial diversion. Records of sample distribution must be maintained, and packaging should be distinctively labeled to indicate that the product is a sample and not for sale. Diversion of samples into commercial channels is a significant regulatory and reputational risk, and sample control is often the entry point for broader investigations of promotional practices.
Hospitality and Educational Activities
Hospitality and entertainment associated with scientific or educational events must be reasonable and incidental to the legitimate purpose of the event. Lavish entertainment, recreational activities unrelated to medical content, and disproportionate hospitality are not permitted. Sponsorship of medical congresses, symposia, and continuing medical education activities is permitted but must be documented, transparent, and structured to avoid creating undue influence. Educational grants and sponsorships of patient associations are permitted but should comply with principles of independence and transparency, grants should not be conditioned on prescribing behavior, and the recipient organization should retain independent control over content.
Scientific Information vs Promotion
An important distinction is between promotional materials, which require regulatory approval, and non-promotional scientific information, which is treated more flexibly but must still meet standards of accuracy. Medical information letters in response to specific HCP inquiries, scientific exchange at congresses, and disease awareness materials may fall in the non-promotional category, but the boundary is not always clear-cut, and what is positioned internally as scientific information is sometimes characterized by the regulator as promotion. Sound internal review processes help draw the boundary in defensible places.
Digital Channels
Digital and social media promotion has introduced new compliance considerations. Iraqi advertising rules apply to digital communications directed at Iraqi audiences regardless of where the server is located or the sender resides. Pharmaceutical companies should ensure access controls for HCP-only content, comply with language and approval requirements, and have policies for handling unsolicited online inquiries. Influencer marketing involving medicines is particularly fraught, the appearance of personal endorsement of a product creates risks that companies should manage actively rather than tolerate as part of a broader social media strategy.
Anti-Corruption Considerations
Pharmaceutical advertising and promotion intersect with anti-corruption considerations. Many HCPs in Iraq are employees of public hospitals or universities, qualifying as public officials for the purposes of laws such as the US Foreign Corrupt Practices Act and the UK Bribery Act. Improper benefits provided to these individuals can trigger liability under Iraqi law and under extraterritorial regimes with consequences well beyond Iraq itself. Engagement of HCPs as speakers, advisors, or consultants is permitted, but it must be properly documented, with written contracts, scope-of-work descriptions, market-rate compensation, and records of services delivered and the engagement should fulfill a genuine business need rather than serving as a vehicle for inappropriate benefits.
Penalties
Penalties for non-compliance with advertising rules range from withdrawal or amendment of promotional materials, through fines, to suspension of marketing authorization in serious or repeat cases. The reputational consequences can be significant, and HCPs involved in non-compliant promotional activity may face sanctions under their own professional codes. International companies should align their local and global compliance standards, ensuring that activities permitted under more lenient regimes are not extended to Iraq inappropriately.
How We Can Help
Etihad Law Firm advises pharmaceutical companies on the legal aspects of medicine advertising and promotion in Iraq, including review of promotional materials, training of commercial teams, design of compliance programs, and defense in administrative actions and investigations related to promotional practices.